Dr. John Cush RheumNow
3 years 3 months ago
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
https://t.co/oNTKZXSrzn https://t.co/OlbCuSuLlo
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA). This has implications on diagnosis and population care. A recent analysis of Norway registry data answers this question.
Dr. John Cush RheumNow
3 years 3 months ago
In the UK, MHRA has somewhat softened its warnings on Febuxostat use in gout - stating use caution if considering Febuxostat in patients with a prior history of major cardiovascular disease; esp w/ high urate and tophi burden or starting ULT https://t.co/y0KhXtgzzG https://t.co/5ZlE0XK8qx
Dr. John Cush RheumNow
3 years 3 months ago
The Burden of Chronic Pain in US Adults (2019-2020)
Analysis of National Health Interview Survey data shows that the incidence of chronic pain in the USA is high compared with other chronic diseases.
https://t.co/mH6Zb3i3Vw https://t.co/PWI8R6mKJR
Dr. John Cush RheumNow
3 years 3 months ago
J&J lawsuit against Amgen (Nov 2022) over Amgens biosimilar of Stelara has been settled (terms undisclosed) such that the Amgen biosimilar cannot be US marketed until 1/1/2025. Stelaras 2022 revenue was $9.7 billion https://t.co/NVgBsBNxk1 https://t.co/Fj8rn05RW0
Dr. John Cush RheumNow
3 years 3 months ago
Women’s health research lacks funding – these charts show how -- Nature has published a very slick/graphical representation of the deficient research funding (US NIH & UK UK Medical Research Council) of diseases affecting women. https://t.co/hJ8DzKxHeW https://t.co/aHoQTKOlRF
The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.
Dr. John Cush RheumNow
3 years 3 months ago
With all the new adalimumab biosimilars happening in 2023, where's the pen? Now the FDA has approved an ADA biosimilar, Cyltezo, Autoinjector Pen! https://t.co/yyyPa9d2Ye https://t.co/MuAnfJ0DsB
Dr. John Cush RheumNow
3 years 3 months ago
A call for the NIH to address disparities in women’s health research funding. In 1993 Congress mandated NIH include women/minorities in clinical trials. But 30 yrs later, only 11% of NIH budget went to womens diseases https://t.co/8yzUTD1Ufq https://t.co/27W6MnRCFx
Dr. John Cush RheumNow
3 years 3 months ago
Retrospective cross-sectional EMR study from Israel compared GI Dz in 18,598 FM pts vs 36,985 controls. FM significantly assoc w/ IBS (OR 4.61), GERD (OR 2.62), PUD (OR 2.13), celiac Dz(OR 2.08), IBD ; But not w/ GI malignancies https://t.co/mpLb3rE0CB https://t.co/mySSXC5sjA
Dr. John Cush RheumNow
3 years 3 months ago
SLE & dsDNA: 3,484 SLE pts (over 37,582 visits) - 29.5% had persistently dsDNA+ & 34% had fluctuating dsDNA.results & both assoc w/ SLE flares (HR 1.56 & 1.46). Doubling of dsDNA assoc w/ 33-36% increased risk of flare (p=0.009) https://t.co/quVlHrfSl3 https://t.co/DkD3h1wV6w
Dr. John Cush RheumNow
3 years 3 months ago
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/j119qQ0alv https://t.co/pVRO6SfiaI
Dr. John Cush RheumNow
3 years 3 months ago
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different?
#RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs
